What is the confirmed market size and growth trajectory for the swine healthcare market?
The market was valued at USD 3.9 billion in 2025 and is projected to grow at a CAGR of 6.5% to USD 6.87 billion by 2035. PRRS and PCV2 vaccines are the dominant product categories. Anti-infectives are under stewardship pressure but therapeutically significant. Asia-Pacific is the dominant region by swine population; North America and Europe lead by technology adoption. Precision livestock technology is the fastest-growing product category.

How does PRRS define the swine vaccine market?
Porcine reproductive and respiratory syndrome — a highly mutable RNA virus causing respiratory disease, reproductive failure, and high piglet mortality — is the most economically costly swine endemic disease globally, estimated to cost the U.S. pork industry approximately USD 664 million annually. PRRS vaccines are the dominant swine health product category by revenue, but the virus’s high mutation rate means field strains frequently diverge from vaccine strains — creating continuous demand for updated formulations.

How does African swine fever create biosecurity investment above routine swine healthcare?
African swine fever — a lethal haemorrhagic fever with no approved vaccine (as of 2025) and no treatment — creates extreme biosecurity investment from swine producers in endemic or outbreak risk regions. Biosecurity products (disinfectants, protective equipment, feed security systems), ASF rapid diagnostic tests, and international trade biosecurity protocols represent a distinct market layer above routine vaccination and health management.

How does Dectomax-CA1 conditional approval demonstrate antiparasitic capability for swine?
Zoetis’s conditional approval of Dectomax-CA1 Injectable to prevent and treat New World screwworm — primarily targeting cattle — demonstrates Zoetis’s capability to develop and receive conditional regulatory approval for emergency antiparasitic products in response to emerging parasitic disease threats that can affect swine. This conditional approval capability creates commercial pipeline optionality for swine-specific antiparasitic innovations addressing emerging disease threats.

How does precision livestock farming improve swine health ROI?
Zoetis’s precision livestock farming technologies — genetic tests for pig production trait prediction, biodevices for individual animal health monitoring, and data analytics platforms — enable commercial pork producers to identify sick individuals within large pig groups earlier than visual observation allows, triggering targeted treatment that prevents disease spread while reducing blanket antibiotic use. This precision approach improves health outcomes while supporting AMR stewardship compliance.

How does antimicrobial stewardship affect swine anti-infective market composition?
EU Regulation 2019/6 restrictions on prophylactic and metaphylactic antibiotic use in swine, combined with U.S. VFD requirements for veterinary authorisation of medicated feed antibiotics, are shifting swine anti-infective use from blanket prophylaxis toward targeted therapeutic treatment. This transition reduces total antibiotic volume but sustains or increases the value of targeted therapeutic anti-infective use.